LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

Kodu・Aktsiate loetelu・Arbutus Biopharma Corp

Arbutus Biopharma Corp

Suletud

4.29 -4.24

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.29

Max

4.33

Põhinäitajad
By Trading Economics
Sissetulek	4M -3.8M
Müük	522K 1.1M
Aktsiakasum	-0.014
Kasumimarginaal	-357.374
Töötajad	44
EBITDA	-1.1M -8.8M

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	13. mai 2026

Turustatistika
By TradingEconomics
Turukapital	12M 851M
Eelmine avamishind	8.53
Eelmine sulgemishind	4.29

Tehniline skoor

By Trading Central

Kindlus

Weak Bearish Evidence

3.255 / 3.365 Toetus ja vastupanu

Arbutus Biopharma Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

27. märts 2026, 17:33 UTC

Uudisväärsed sündmused

ECB Should Not Rush Its Response to Iran Conflict, Says Schnabel -- Update

27. märts 2026, 17:00 UTC

Uudisväärsed sündmused

ECB Shouldn't Rush Its Response to Iran Conflict, Schnabel Says

27. märts 2026, 16:03 UTC

Uudisväärsed sündmused

Fertilizer Maker Yara Warns Farmers Are Being Squeezed by Price Surge Amid War -- Commodities Roundup

29. märts 2026, 23:47 UTC

Market Talk

Uudisväärsed sündmused

Gold Falls Amid Rising Inflation Fears -- Market Talk

29. märts 2026, 23:46 UTC

Market Talk

Uudisväärsed sündmused

Nikkei May Fall on Fears About Shortage of Petrochemical Products -- Market Talk

29. märts 2026, 23:35 UTC

Market Talk

Uudisväärsed sündmused

Oil Rises on Supply-Disruption Concerns Spurred by Widening Mideast Conflict -- Market Talk

29. märts 2026, 23:23 UTC

Market Talk

Australia's National Cabinet to Avoid Covid-Style Measures -- Market Talk

29. märts 2026, 22:34 UTC

Market Talk

Macroeconomic Tailwind for Warehouse Dissipates -- Market Talk

29. märts 2026, 22:09 UTC

Market Talk

Amplitude's Next Well "Effectively a Must-Win" for Growth Thesis -- Market Talk

29. märts 2026, 21:06 UTC

Market Talk

Uudisväärsed sündmused

Australia's Economy Could Already Be Contracting Amid Oil Shock -- Market Talk

29. märts 2026, 21:03 UTC

Market Talk

Australia's Government Wants to Avoid Heavy Handed Oil Shock Response -- Market Talk

29. märts 2026, 21:01 UTC

Market Talk

Uudisväärsed sündmused

Australian National Cabinet Meeting to Focus on Oil Supply -- Market Talk

29. märts 2026, 09:30 UTC

Omandamised, ülevõtmised, äriostud

Food Mega-Mergers Hardly Ever Work. Could McCormick-Unilever Be Different? -- Heard on the Street -- WSJ

28. märts 2026, 08:20 UTC

Market Talk

Health Care Roundup: Market Talk

27. märts 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

27. märts 2026, 19:16 UTC

Market Talk

Uudisväärsed sündmused

Oil Futures Rise On Uncertainty Ahead of Weekend -- Market Talk

27. märts 2026, 19:07 UTC

Market Talk

U.S. Natural Gas Gains As April Contract Expires -- Market Talk

27. märts 2026, 19:04 UTC

Market Talk

Gold Rises But Can't Finish the Week Positive -- Market Talk

27. märts 2026, 19:03 UTC

Market Talk

Uudisväärsed sündmused

Global Forex and Fixed Income Roundup: Market Talk

27. märts 2026, 19:02 UTC

Market Talk

Uudisväärsed sündmused

Among Central Banks, Canada Has Room to Handle Oil Inflation -- Market Talk

27. märts 2026, 18:12 UTC

Market Talk

Foreign Fuels and Feedstocks to Get RINs Until 2028 -- Market Talk

27. märts 2026, 17:36 UTC

Uudisväärsed sündmused

The Iran War and Oil Prices Bring Risk of Deeper Market Lows. There Are Echoes of 2008. -- Barrons.com

27. märts 2026, 17:34 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Delivery Hero Shares Bounce as Stake-Sale Report Whets Investor Appetites -- Market Talk

27. märts 2026, 17:29 UTC

Market Talk

U.S. Oil Rig Count Falls By 5 to 409 -- Market Talk

27. märts 2026, 16:38 UTC

Market Talk

Carnival's Outlook Assumes Oil Prices Will Come Down -- Market Talk

27. märts 2026, 16:32 UTC

Market Talk

Uudisväärsed sündmused

Chinese Exposure to Higher Energy Costs Seen as Limited -- Market Talk

27. märts 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

27. märts 2026, 15:43 UTC

Market Talk

Uudisväärsed sündmused

Hormuz Closure Sends Tanker Rates to Record Highs -- Market Talk

27. märts 2026, 15:25 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27. märts 2026, 15:25 UTC

Market Talk

Swiss Franc Dented by Rising European Yields, SNB Intervention Threats -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Arbutus Biopharma Corp Prognoos

Hinnangu Konsensus

By TipRanks

0 ratings

Osta

Hoia

Müü

Põhineb 0 analüütiku instrumendi Arbutus Biopharma Corp aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

3.255 / 3.365Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.